Compare
Glaukos Corp vs AtriCure, Inc. vs Bioventus Inc. vs Artivion, Inc.
| Latest fiscal year | Glaukos Corp GKOS | AtriCure, Inc. ATRC | Bioventus Inc. BVS | Artivion, Inc. AORT |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $507.44M | $534.53M | $568.09M | $441.33M |
| Revenue growth (YoY) | +32.3% | +14.9% | -0.9% | +13.6% |
| Gross margin | 55.7% | 75.0% | 68.3% | 64.4% |
| Operating margin | -39.3% | -1.8% | 9.5% | 7.6% |
| Net margin | -37.0% | -2.1% | 4.0% | 2.2% |
| Net income | -$187.69M | -$11.45M | $22.73M | $9.77M |
| EPS (Diluted) | -$3.28 | -$0.24 | $0.33 | $0.21 |
| Operating cash flow | -$14.79M | $57.33M | $74.67M | $39.88M |
| Free cash flow | -$22.45M | $48.28M | $72.11M | $839.0K |
| Cash & equivalents | $90.81M | $167.43M | $51.24M | $64.91M |
| Total assets | $893.49M | $654.18M | $683.56M | $884.80M |
| Total liabilities | $237.33M | $162.24M | $455.11M | $436.56M |
| Shareholders' equity | $656.15M | $491.94M | $184.10M | $448.23M |
| Return on year-end equity | -28.6% | -2.3% | 12.3% | 2.2% |
| Shares outstanding | 57.51M | 49.79M | n/a | n/a |
Revenue, most recent five fiscal years
| Fiscal year | Glaukos Corp | AtriCure, Inc. | Bioventus Inc. | Artivion, Inc. |
|---|---|---|---|---|
| Latest | $507.44M Ended 2025-12-31 | $534.53M Ended 2025-12-31 | $568.09M Ended 2025-12-31 | $441.33M Ended 2025-12-31 |
| 1 year earlier | $383.48M Ended 2024-12-31 | $465.31M Ended 2024-12-31 | $573.28M Ended 2024-12-31 | $388.54M Ended 2024-12-31 |
| 2 years earlier | $314.71M Ended 2023-12-31 | $399.25M Ended 2023-12-31 | $512.35M Ended 2023-12-31 | $354.00M Ended 2023-12-31 |
| 3 years earlier | $282.86M Ended 2022-12-31 | $330.38M Ended 2022-12-31 | $512.12M Ended 2022-12-31 | $313.79M Ended 2022-12-31 |
| 4 years earlier | $294.01M Ended 2021-12-31 | $274.33M Ended 2021-12-31 | $430.90M Ended 2021-12-31 | $298.84M Ended 2021-12-31 |